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Conclusions: The majority of RRD segments on thallium.201 had sup. 
pressed fatty-acid metabolism with wall motion abnormality in the acute 
phase, b.t wag motion abnormality of the RRO segments improved with 
recovery of fatty.acid metabolism in the follow.up phase, 
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~ Flbrlnolytlc by Estrogen Therapy Potentiation it 
Conventional gouge In Poetmenopauul Woman 
la Independent of  Co |gu l |Uon  Pathway Activation 
K,K, Koh, M,K, Home, lit, R,O, Cannon, IlL NHLe/~nd Gila/col P~thology 
D~ffrnr~f, NIH, eel/made, MO, USA 
Estrogen usa in ge~,erql h~a boon ~0soolaiod with in~ ,~aaed risk of venoos 
thmmboomboll and hU b~n shown to S~tlvete do,~a,dapandentty coag, 
ulation I~thw~ya, We h~vo recently shown that oral 0strogen therapy af 
conventional dosage potentiltet fibrinotysls In postmanopausal woman, n 
pfootaa 1hat could !~ A ¢one@quonco f prim~n/aatrogen.lnduced oeagu. 
lotion a~llvetion, To ease l  the mechanism of aahogan.lnducod flbrtnotysis, 
we mouu~ l~ramaters of cougulation aotlvstion [pmthrombln fmgmenh,~ 
(F~.~), thrombln.~nttthrombln (TAT) complexes] and pemmatem d llbrinol. 
yltis potentiation ~lSUe,type ptssmlno;~n a¢tivetor (t,PA) and plasmlnogen 
~stiv~ter inhibitor (PAid) s(:tivitioa] st l~asllne and following 1 month of con- 
lugeted ~quine estrogen (GEE) 0,~5 mg administered to g postmenopeusal 
worlds, 
R~u/~: (data ,. mean ± SO): CEE marginally increased F~.= by 18 ~ 3 f % 
(P ,= 0.14) and nonsignlticanfly increased TAT by 6 ± 50% (P ,= 1.00), GEE 
reduced PAid activity by 38 ;L 30% (P - 0,03) and (ncressnd t.PA activity by 
68 • 8S% (P. 0,09), There was no association between % ~,TAT sod %,M.PA 
(r - 0,0S), and the associations between %&TAT and %SPAt.1 (r =~ 0393), 
%~F~,~ and At.PA (r = -0,60), or %.~F~,~ and %~PAI.1 (r : 0,527) were 
dtmotionally opposite anttclpatt~l correlations If potentiation of flbflnolysls was 
a result of coagulation activation, We conclude that petentiation of tibrtnolysls 
Is a prims~/eltect of GEE at the dosage used in our study and likely accounts 
for the low risk of venous thrombeambolt In postmsnopausal women taking 
at conventional dosage of fNs preparation. 
~ T h e  L-Arglnlne: Nitric O~lda Pathway Contributes 
to tho Acute Release of Tissue Plasmlnogan 
Activator In vlvo In Man 
O,E, Newhy, R,A, Wright, P, Dawson, C,A. Ludlam, N,A, Boon, K,A,A, Fox, 
03. Webb. Un/vers/ty of Edinburgh, Edinburgh, UK 
e~:k ,~:  Effective endogenous flbrinolysls requires rapid release of en- 
aoth~ilal tissue plasminogen activator (t.PA), Using the nitric oxide synthase 
inhibitor, L.Na-monomefhylarginlne (L.NMMA), we examined the contribu- 
tion of endogenous nitric oxide to substance P induced t-PA release In Wvo 
in msn. 
Methods: Blood flow and plasma fibrinolytic and hemostetic factors were 
measured in both forearms o1 8 healthy male volunteers who received uni- 
lateral brochisl artofv infusions of substance P (2.-.8 pmol/mln) and L.NMMA 
(1-4 #tg/mln), 
Resu~: Substance P caused dose-dependent increases in blood flow (p 
< 0.001) and plasma t-PA antigen (p = 0,04) and activity (p < 0,001) con- 
centretiens confined 1o the Infused forearm but had no effect on plesminogen 
activator Inhibitor type I (PAl-I) or van Wlllebrend factor concentrations. In 
the presence of L*NMMA, substance P again caused significant increases 
in blood flow (p < 0.001) and t-PA antigen (p = 0,003) and acti.:lty (p < 
0.001) concentrations but these increases were significantly less ~han with 
substance P alone (p < 0.001, p = 0`05 and p < 0,01 respectively) _-NMMA 
alone significantly reduced blood flow in the infused arm, but had no mea- 
sureable effect on t-PA or PAl-1 concentrations. 
Conclus/ons: The Loarginine:nitric oxide pathway contributes to .~ =bstance 
P induced t-PA release in viva in man, Tills orovides an impodent po- 
tentisl mechanism whereby endothelial dysfundton increases the ris~ of 
atherothrom0osts hrough e reduction in the acute fibrinolytic apacity. 
~ T h e  Estrogen Receptor AgonlaVantagonlat 
Temoxlfen Improves Endothelial Function In 
Poatmanopausal  Woman 
J, Lek~kls, C, Papamicheel, P, Athsnssladls, N. Desses, C. Vammos, 
A, Gika, A, Voutsas, S. Stsmatsiopouios, "Alexendra" Unlverslly Hosp#al, 
Athens, Greece 
Previous breast cancer tmatmont rials using tomoxtten, have reported s@- 
nltlcont reduction of cardiovascular events, Since endothelial dysfunction is 
an eady alga of aiherosclemsls, we assessed endothelial function in 13 post. 
menopousal woman recolvlng temoxlfon as monothempy lot breast ~ncer 
(mean daily deso P.1 .~ 3 mgr, duration of ~matmenl 38 4:21 months, age St ± 
9 yosm), No patient was dlal~tla of smoker, Cholesterol was 2t ? ± 28 mg/o't, 
Triglycofldes t8"/± 70 mg/dl nnd HDL chol 50 ± 20 m0/¢ll, Bmchial oftory 
diameter in response to hYl~remle flow (endotholium,de~ndanl shmulu@ 
and to aubllngual nitroglycerin (e,ldothelium.indepondent vesoddetof) was 
assessed by high resolution ultrasound imaging, Resu~ were ¢oml~lred to 
13 age and aox.matched healthy controls, Cholesterol and HOt. ehoteatefol 
ware ¢omlmtabla in two gro,Jps but Iriglycondes were higher in patXmts m- 
~ejving temoxt~n (t87 ~ 70 ve 138 ± 52 mg/dl, p = 0,05), Bsselil~ diameter, 
t~selina flow ~nd degree of rt~clivO hyperomis were similar in two groups, 
Flow,mediated dilatetion w~s hlghor in p~tiente ~ iv lng  temoxiten (125 ± ? 
ve 8 ~ 3,5%, p = 0,05) while nihoglyoefln.indgced ilatation was (mmparabte 
in two groups (2? ¢ 12 ve 25 ± 10%, ns), intimating an improvement o1 
endothelial fun(,'tion in temoxttan group, 
In ~htsk~;  this study p,ovid~ evidence thai tamoxiton IrJada Iio ira, 
prevement o! endothelial function in postmeoopausal women Ihat is inde- 
pendenl o! cholesterol reduction, which my contnbuto to a docmese m 
eaMiovascuior morbidity and mortslity in these su~.  
~ Long-term Estrogen Therapy  Improves 
Endothelial Funatlon In Women With Rayneud's 
Phenomenon 
J, t.ekakis, C, Papamichael, M. Mavnkakis, A. Vouleas, S. StamatetopeuIos. 
"Atexandra" Univ. Hosp, Athens. Greece 
Endothelial dysfunction is present in palmate with Rayneud's phenomenon 
secondary to system~ sclerosis and acute estregen edmmtstrolion can .n- 
prove this dysfunction. It ie not known whether Iong-telm estrogen therapy 
Improves endothelist function too, We therefore xamined the impact o1 tong- 
term estrogen therapy on endothelial function in 9 women with Rayneud's 
phenomenon secondary to systemic sclerosis (age 58 ± 8 years, range 
47--71 ). We used high resolution ultrasound to image the brechisl affe,'y; the 
diameter was measured at baseline, during reactive hyperem~a to assess 
flow.mediated eedothelium-dapendent dilatation (FMD) and Iollowing sublin- 
gual nitreglycenn to assess endothelium-independent vasodilatlen. FMD m 
patients (pts) was significantly lower compared to 10 female controls of simP- 
ler age (2.1 ± 1.6% vs 8.2 ± 3.2%, p = 0`000); also endothelium.independent 
dilafstlen was reduced in pls (17.6 ± 4.8% ve 26 ± 8%, p = 0.01). Patents 
were entered into a randomized, double-blind, placebo controlled, crossover 
trial (4 weeks washout phase) st conjugated estrogens (Premann 1.25 mg 
per day for 4 weeks). No significant changes were seen in vessel szze, rest 
blood flow, degree of reactive hyperemla, cholesterol, togtycendes, HDL 
LDL. Estrogen did not affect endothalium-independenf dilatation compared 
to placebo (22.6 + 9.1% vs 19.1 ± 6.9%, as). FMD was greater with estrogen 
(6.6 ± 3.5%) as compared with placebo (1.5 ± 2%, p < 0`05). In conclusion 
long term estrogen therapy markedly improves abnormal endothelial function 
in pto with Raynaud's phenomenon. This, beneficial effect is not related to 
changes of lipid profile. 
~ U s e  of  Synchrotron Radiat ion Mlcroangiography 
to  Assess Endothel lum-dependent  Relaxation of  
Microvessels in a Rat Model  o f  Hlndllmb Ischemla 
S. Takesh[ta, 1". tsshiki, Y. Mlyazawa, K. Eto, M Ochiai, E. Tanaka, H. Mori, 
T. Sato. Department of Medicine, Teikyo University Hospital, Tokyo, Japan 
Background: Current methods of anglegrephy cannot provide images of ar- 
teries measuring less than 200/~m in diameter. We have recently developed 
a new angl,~gropl.y system which employs monochromatic synchrotron ra- 
diation (SR) and high-definition video system with a spatial resolution of 30 
l~m. In the present study, usilLo this microanglegrophy system, we sought to 
document endotnelium-dependont relaxation of microvessels in the normal 
and the Ischemic rot limbs. 
Methods: tschemia was induced in one limb of rats by excision of a 
femoral artery. Thirty days later, SR microanglegraphy was performed to 
assess endothelium-dependent vasomotor esponses of microvessels (n = 
26). 
Results: SR microangiography clearly visualized the fine network of mi- 
crovessels (< 100/~m in diameter) in both the normal and the ischemic limbs. 
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In the normal limb, up to the 4th l~anch~ of the lltim an¢or femoral artanes 
were re=Kldy Identified. In the It~-han~ limb, an extan~ive structural remod. 
eling of the vescular netwo~ (l.e, collateral) was observed. Ao~nistmtton of 
Iicotylchoflne Induc~ II ~ dilate1 of ~ intcrovusets In the non~ll 
limb whil~ ~nly II mod(~t dtlat~l in fire i~'h~rnk: limb, MOfl~5~)gic~l asseu- 
merit of collateral ~ r ~  ~ that ~uch i~la~em of va~o~'  
rnporm~ m more evident in coflatm~t~  an umlul~ng app~re~ 
than thoN with a limm~ NX~em'anc~, 
Co~@~=~ 11~ l~mt  ~udy ~ l y  0ocumerttt~ lot tt~e ~m 
tu~ (1) ~ ~othe l lum-d~tmd~ mlmmtior~ of ~ wtlh a m~olw 
t~ l  limit I~low 100 ~ m and (;~} th~ prmmn¢~ of d ~  (mdolt~ium.de~pe~ 
d~t  vam~ma~ mqx.~m~ among maat~m ~ d~in9  ~ ,  
mJcrove~m mac~ty, and may he~ to ~ .ew m~ mgamtn~ me 
coftat~al micmOmula~o 
1 t!81-5,?.| NI1~ 0xki~ !~dkm~ ~ m k ;  ~ o! 
l ' l b -E l~NIo l  
M~m E, Bey~, Ge~g Yu~ H~n~ Mamn ~ t ~ .  &l~k-a~ ~o~a~, 
of the tmal ~=nd m~a~o~. ~ ~ ~ of ~TO.E may ~ 
~ by nmtc o=de (NO). ~ v~y t~m ~ we ~ me 
~ of NO ~ ~ m ~ ~ enms Of es~0m 
In VW~. 
~ ~ ~ rm me ~ of 200 n0~ tT~.E m compared 
w~h ~ ~ and wire ~ v~ me NO Wnmem 
~ L-NAME (100 ,g~0). B,m,v.s measumme~s in me m~act c~s~mn 
q.an~cam~ of myoca~d m~racmy ~ of pmmm vascu~ 
enec~ 
L-N/~E ~ L-N~I~E 
17~l-lE NaCI t7t~JE NaCl 
Ca~tl=ac OUtlp~t 167:10" 108=5 109±2 113¢2 
I ~  tractmn 127 ~: 3" 98±3 104±3 105:=5 
P e ~ ~  71±3" ~±4 93=2 ~2±3 
Iso~oi_ LVSP 97:4  g2±3 ~±I  98±1 
~ drddlm~ 97¢4 102±3 101 ± I 98:=2 
Means ± SEM m % o~ we~hmon v~__ _,,~_." = p < O001 
17p-E mcreasos the can/mc ~ and the eiectmn I~mn due to a 
reduct~n of the aftsdoad. These effects are al0o;,~,e,.i afire ~ 
troth L-NAME. Neither witloJt nor v~ith L-NAME an ~tDlmpc effect of 17,'1-E 
~s ¢lemctab~ in wo.  
Conc/usk~t~s- The hemodynam~ effects of 17p-E due to ~ of ~e 
a~toad am mediated by act~at~g me NO-pamway =nce ml~Z~on of 
NO Wnmes,~ by L-NAME ~ pn~ents the vaso¢~h~Ne ef~=cts of 
17p-E m vwo. 
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i -~"2"~-'1 Soluble Molecule P-Selectln and Adhesion 
Beta-ThromboglobulIn as Markem of Platelet 
Activation In Hypedension 
G.Y.H. Lip, A.D. Blann, I.F. Islim, D.G. Beevem./-/aemostasis Thmmbos~ & 
Vascular Biology Unit. UniverSity Department of Medicine, City Hospital. 
Birmingham. England 
Backgrou;x1: Despite the artana; tree being exposed to high prss~u~eS in hy- 
pertensive pattents, the complications of hypertension (strOkes. hear attacks) 
am paradoxically thmmhet~c rather than haemonhag¢. The coagulation sys- 
tem may thus be impodant in hypertension, leading to a hypercoagulable 
state. 
Aim and Method: To test the hypothesis that the hypercoagulable state 
in hypertension involves platslet activation, we measured 2 platslet activa- 
tion markers, soluble P-selectin and beta thrombogiobulin, by ELISA in two 
studies of untreated patients with hypertension. Levels were compared with 
corrcsponding age- and sex-matched controls. 
Results: Soluble P-selectin levels at a median of 300 ng/mL (range 
190-800 ng/mL) in 100 hypertensive patients (mean BP 162/98 mm Hg), 
were significantly elevated compared to levels in normotensive controls (228 
ng/mL (range 17S-412), p < 0.05), In the ~m¢o~d ~tudy, mean ~ #yore- 
hog. in  ~ were S8 ntyml. (40-?'/) m 40 hypemmmse (l S/101' rm 
Hg). which was I~nt ly  elevated compared to ~ mean of 3~ ng/mL 
(27-,,%) m 2~ cor(ffofs (p < 0.01). Twenty of th~ pat~ntl m i p _ ~  
treated w~th I0 rng qk, na~nl daffy tot 12 w~kl  In an open fNNon. Mean OP 
from 1~/117 mmHg to 151/98 I I~ H 0 ~ ~ p < 0.001), wh~h 
from ~9 ngtmt. (45-106) to 46 n~m~ (3~1-.~) (pllf~d ~ p < 0.0S). 
Co~tm~: In,~'mat~  of 2 mmem oh~m~t ~ m t~x.~ 
t ,m~ mmmml molvt, mm of ~ m m,..m~og~m, w,~ my 
~x,,~m~ to the mmmtx~ m~mm~ ~ hy~tm,  m, ~ ~.  
~W may ~mft~ I~ wamm~ m hyt~ttmme ~ ,  ~."J'.~.,Rh hem~ 
in ~k~l  a¢lwatmn. 
• Po lymofph l lm of  e~( Idgt~ ~ I , ~ m  
S ~ ,  N. Iwai, Y Tl~itn, N ~ ,  Y. Nakamum, M Kmosh~, ~ 
unm~ Of ~v~al  So~x~ Om. Jar~ 
of ~ at amino aod num~ 4e0) ha~ t~en relpo~ed to be morn ram, 
mon mong I~ar~n and French hV~e,em~ m(~,_ ~ Ban amon~ contrail. 
Momo,~. r~x ,m~ms md,~ _~1-~ w~m T ~  h~ t~m mpomm to em~ 
~ ~ ~ ~ m ~d~um behe~o e~d a ~mmm h~ in ~ 
p~mum m mspome to dJum~ tma~nem. In ~e pmmmt n.,dy, we In~S- 
gene and ~ in a .J~pa~se ix~publ~m~ 
~d~ The m, dy pq~n comamd Of ;m3 s~- ts  m~md ~ 
bo,~e~ (8. n = T~). and hypemm~ (HT. n = ~3) gmup~ The cram 
fm NT ~ _h~,~_ pm~'~_ _'re (eP) le~ man 150~0 mmHg and age eto~ S0 
~rs  o1¢1. Theottana lot HTwa= BP moml~m 150~S mmltg. Tha gmotype 
of a __-,~,~,_ .~-m .a~ demmmea by a~ele mmr~ ~ hyl~idizaZk~ 
R~s:  The _fre~_ _,,_,~'y of ere get .n -  Gay,moTto po,'vmoMmm  
sig~fica~ty different among Ihe NT, B, and HT groups (p = 0.0113). Tha GG 
genoq~e Of ltte adduon gen~ m morn common m tt~ NT group (20.4%) 
man m I~e HT group (7.1%). ~ .  ~m T~460 tdlele m mgnlfom~ 
omm hand, ~s  ~ had no s~-T ,~ e~c~ on k~fl venmcu~ 
~ The prom mdy s~0em ma~ G~m)Tm po~mm~sm 
at the a ~  ~=-~ may he involved m ~ ~ of the 
~w-mmn type, among ~ .  
'82-'~7-~ Thmmbomodulin and Tissue Factor Pathway 
Inhibitor Levels as Risk Factom In PMkmls With 
E, mmUal HVpem.=~ 
Th.K. ~akrts, p.G. K ~  G.P. Anastsmadm. T. Dodouras, P. T ~ ,  
AN. Hal2~ahenas, A Pen, akm, M.K. Kynal~]m. ~ Reg. 
B T C ~  La& Del0~ Of ~ / / ( O  Gen. Hosp~al, A~ans. 
Cn~ce 
Back~"  Increased Tmsue Factor Pa~way Inhlbdor ('TFPI) ~ have 
~een rmoru~ m acute ~,~'~.~nic ~ ~ m young mW~Js 
(<40ym). Moreoq~r. ut~,,,~M~-,,~,~In [11d] ~s knowe to have ~hrom~y ~.m 
on b'm~0#k The am~ Of n~s sludy is ~e eveh,,~G~~ of iFf ' i  and TM fe~s 
~ h,nx.~m~uve pahenta t~)m me m~auon of any phamuu:euuc~ mmu.e~ 
and me c:omp~;~ of G-.~e findlngs m me clara dem~d from ~ 
controls. 
Mefhods: Fo~/ mree l~s (23 M, 20 F, age 49-8 ± t0.1, bedy mus 
index 26.6 + 3.9) and forty controls (22 M, 18 F. age 50.1 ± 6.4, BMI 
26.4 + 3.7) w~re included in 1he study. Smokers, oven~ee~lt individuals 
and cl~ahelzcs were e~¢ludecL TFPI and TM leve~s were assayed bY (ELISA) 
an enzyme-I:,nked mm.moassav. ~ sampling was pe~0m~ on 
indndduals at 8-9 am. Sta,aslCal analysis was dor~e with Studenfs t-tesl and 
stsl~sl~al sigr~ficance was su..#.:j~;~l when p < 0.05. 
Results: 
Contro~ p 
TFPI 103.3 + 2828 91.8 • 24 2 10 < 005 
TM 32.5 ± 975 45.6 = 15.17 p < 0.001 
Condus~or~: These, findings 0ncmasod TFPI and decreased TM) tn rela- 
tion with prmnous fir~;r~j~ conceming oh'~er haemostasls parameters, 
port the increased nsk for cardiovascular episodes in hypertensive patients. 
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